474 related articles for article (PubMed ID: 15815732)
1. [Treatment of patients with gastrointestinal stromal tumour with imatinib mesylate].
Haugland HK; Jebsen NL; Mannelqvist M; Skar R; Eide J; Øvrebø K; Horn A; Jensen DK; Monge OR; Lilleng PK
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):868-72. PubMed ID: 15815732
[TBL] [Abstract][Full Text] [Related]
2. [Imatinib mesylate in the treatment of advanced gastrointestinal stromal tumors].
Wan DS; Wu XJ; Pan ZZ; Zhou ZW; Chen G; Li LR; Lu ZH; Ding PR
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(43):3064-7. PubMed ID: 17288838
[TBL] [Abstract][Full Text] [Related]
3. [Imatinib mesylate alone for refractory advanced gastrointestinal stromal tumor].
Shen L; Jin ML
Zhonghua Zhong Liu Za Zhi; 2004 Nov; 26(11):697-9. PubMed ID: 15777512
[TBL] [Abstract][Full Text] [Related]
4. Use of imatinib mesylate in gastrointestinal stromal tumours: Pan-Birmingham Cancer Network experience.
Wong DW; Lupton SC; Bhatt L; Gross L; Tanière P; Peake DR; Spooner D; Geh JI
Clin Oncol (R Coll Radiol); 2008 Sep; 20(7):517-22. PubMed ID: 18514495
[TBL] [Abstract][Full Text] [Related]
5. Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.
McAuliffe JC; Lazar AJ; Yang D; Steinert DM; Qiao W; Thall PF; Raymond AK; Benjamin RS; Trent JC
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6727-34. PubMed ID: 18006774
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate therapy in advanced gastrointestinal stromal tumors: experience from a single institute.
Hsiao HH; Liu YC; Tsai HJ; Chen LT; Lee CP; Chuan CH; Wang JY; Yang SF; Tseng YT; Lin SF
Kaohsiung J Med Sci; 2006 Dec; 22(12):599-603. PubMed ID: 17116620
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of metastatic gastrointestinal stromal tumors with Imatinib: report of four cases].
Garrido S M; Moneada M M; Tapia N G; Méndez O G; Galindo A H; Huete G A; Ibáñez A L; González S; Alvarez Z M
Rev Med Chil; 2007 Oct; 135(10):1327-32. PubMed ID: 18180842
[TBL] [Abstract][Full Text] [Related]
9. Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis.
Mearadji A; den Bakker MA; van Geel AN; Eggermont AM; Sleijfer S; Verweij J; de Wilt JH; Verhoef C
Anticancer Drugs; 2008 Jul; 19(6):607-12. PubMed ID: 18525320
[TBL] [Abstract][Full Text] [Related]
10. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
[TBL] [Abstract][Full Text] [Related]
11. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital.
Yeh CN; Chen TW; Lee HL; Liu YY; Chao TC; Hwang TL; Jan YY; Chen MF
Ann Surg Oncol; 2007 Mar; 14(3):1123-8. PubMed ID: 17195905
[TBL] [Abstract][Full Text] [Related]
12. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
13. [A case of metastatic gastrointestinal stromal tumor developing a resistance to STI571 (imatinib mesylate)].
Miyake M; Takeda Y; Hasuike Y; Kashiwazaki M; Mishima H; Ikenaga M; Mano M; Takada Y; Hirota S; Tsujinaka T
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1791-4. PubMed ID: 15553717
[TBL] [Abstract][Full Text] [Related]
14. Outcome of metastatic GIST in the era before tyrosine kinase inhibitors.
Gold JS; van der Zwan SM; Gönen M; Maki RG; Singer S; Brennan MF; Antonescu CR; De Matteo RP
Ann Surg Oncol; 2007 Jan; 14(1):134-42. PubMed ID: 17080234
[TBL] [Abstract][Full Text] [Related]
15. [Imatinib in gastrointestinal stromal tumor treatment--results from University Hospital Centre Zagreb].
Vrbanec D; Petricević B; Majerović M; Stern-Padovan R; Belev B; Skegro M; Herceg D; Plestina S; Dedić-Plavetić N; Jakić-Razumović J
Lijec Vjesn; 2006; 128(5-6):161-6. PubMed ID: 16910417
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of gastrointestinal stromal tumors with imatinib mesylate: a center-based study of 13 patients].
Bar-Sela G; Lev LM; Kuten A; Wollner M; Haim N
Harefuah; 2006 Jan; 145(1):2-7, 80. PubMed ID: 16450715
[TBL] [Abstract][Full Text] [Related]
17. [New orientations in the management of advanced, metastatic gastrointestinal stromal tumors (GIST): combination of surgery and systemic therapy with imatinib in a case of primary gastric location].
Catani M; De Milito R; Simi M
Chir Ital; 2005; 57(1):127-33. PubMed ID: 15832750
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
Sawaki A; Yamao K; Nakamura T; Suzuki T; Okubo K; Hara K; Kawai H; Yamamura Y; Ito S; Mochiduki Y; Ohno R
J Gastroenterol; 2004; 39(4):329-33. PubMed ID: 15168243
[TBL] [Abstract][Full Text] [Related]
19. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.
Verweij J; van Oosterom A; Blay JY; Judson I; Rodenhuis S; van der Graaf W; Radford J; Le Cesne A; Hogendoorn PC; di Paola ED; Brown M; Nielsen OS
Eur J Cancer; 2003 Sep; 39(14):2006-11. PubMed ID: 12957454
[TBL] [Abstract][Full Text] [Related]
20. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
Griffin JM; Amand MS; Demetri GD
Clin J Oncol Nurs; 2005 Apr; 9(2):161-9. PubMed ID: 15853160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
